Latest Breaking News On - Eric klug - Page 1 : comparemela.com

Novel PCSK9 Inhibitor Reduced LDL by 50%

Lerodalcibep, a third-generation PCSK9 inhibitor, reduced LDL by more than 50% vs placebo in patients with or at a high risk for CVD in the phase 3 LIBerate-HR trial.

LIBerate-HR: Lerodalcibep Lowers LDL More Sharply Than Placebo Over 1 Year

The novel agent has shown no immunogenicity issues thus far and might be a promising new PCSK9 inhibitor option.

Monthly PCSK9 inhibitor cuts cholesterol by half on top of statin, ezetimibe therapy

Novel PCSK9 Inhibitor Cut LDL Cholesterol Levels by More Than Half

90% of high-risk patients on lerodalcibep achieved guideline-recommended cholesterol targets

Lerodalcibep reduces LDL cholesterol by over 50% in high-risk patients

Among patients at high or very high risk for a heart attack or stroke, the addition of the investigational drug lerodalcibep to standard cholesterol-lowering medication for one year reduced LDL, or "bad" cholesterol, levels by more than half on average, compared with a placebo.